PT100441A - Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso - Google Patents

Info

Publication number

PT100441A

PT100441A PT100441A PT10044192A PT100441A PT 100441 A PT100441 A PT 100441A PT 100441 A PT100441 A PT 100441A PT 10044192 A PT10044192 A PT 10044192A PT 100441 A PT100441 A PT 100441A

Authority

PT

Portugal

Prior art keywords

formula

cyclopentyloxy

methoxyphenyl

substituted

mmol

Prior art date

1991-05-02

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
• 238000002360 preparation method Methods 0.000 title description 3
• 150000001875 compounds Chemical class 0.000 claims description 227
• -1 2-imidazolyl Chemical group 0.000 claims description 119
• WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 64
• 229910052739 hydrogen Inorganic materials 0.000 claims description 51
• 239000001257 hydrogen Substances 0.000 claims description 46
• 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 42
• 102000003390 tumor necrosis factor Human genes 0.000 claims description 41
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 35
• 238000006243 chemical reaction Methods 0.000 claims description 34
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 33
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 32
• 125000000217 alkyl group Chemical group 0.000 claims description 31
• 150000002431 hydrogen Chemical class 0.000 claims description 23
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
• 238000000034 method Methods 0.000 claims description 22
• 238000004519 manufacturing process Methods 0.000 claims description 21
• 201000010099 disease Diseases 0.000 claims description 20
• 229910052736 halogen Inorganic materials 0.000 claims description 19
• 150000002367 halogens Chemical class 0.000 claims description 19
• 230000002401 inhibitory effect Effects 0.000 claims description 17
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
• 229910052794 bromium Inorganic materials 0.000 claims description 14
• 150000003839 salts Chemical class 0.000 claims description 14
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 11
• 125000003118 aryl group Chemical group 0.000 claims description 11
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 10
• CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 claims description 10
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
• 229910052760 oxygen Inorganic materials 0.000 claims description 10
• 230000009467 reduction Effects 0.000 claims description 10
• 229910004013 NO 2 Inorganic materials 0.000 claims description 9
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
• 229910052799 carbon Inorganic materials 0.000 claims description 9
• 229910052731 fluorine Inorganic materials 0.000 claims description 9
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
• 239000003814 drug Substances 0.000 claims description 8
• 125000001153 fluoro group Chemical group F* 0.000 claims description 8
• 229910052740 iodine Inorganic materials 0.000 claims description 8
• 229910052757 nitrogen Inorganic materials 0.000 claims description 8
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 7
• PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 claims description 7
• 229910052801 chlorine Inorganic materials 0.000 claims description 7
• 230000001404 mediated effect Effects 0.000 claims description 7
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 6
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 6
• 208000026935 allergic disease Diseases 0.000 claims description 6
• 230000000172 allergic effect Effects 0.000 claims description 6
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims description 6
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
• 208000027866 inflammatory disease Diseases 0.000 claims description 6
• 125000006239 protecting group Chemical group 0.000 claims description 6
• 229910052717 sulfur Inorganic materials 0.000 claims description 6
• 125000003831 tetrazolyl group Chemical group 0.000 claims description 6
• 239000003795 chemical substances by application Substances 0.000 claims description 5
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
• 235000019000 fluorine Nutrition 0.000 claims description 5
• 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 5
• 125000005843 halogen group Chemical group 0.000 claims description 5
• 125000000623 heterocyclic group Chemical group 0.000 claims description 5
• 125000002883 imidazolyl group Chemical group 0.000 claims description 5
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
• 125000002971 oxazolyl group Chemical group 0.000 claims description 5
• 230000008569 process Effects 0.000 claims description 5
• 125000003226 pyrazolyl group Chemical group 0.000 claims description 5
• 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims description 4
• 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims description 4
• 239000002168 alkylating agent Substances 0.000 claims description 4
• 229940100198 alkylating agent Drugs 0.000 claims description 4
• 150000001408 amides Chemical class 0.000 claims description 4
• 239000003054 catalyst Substances 0.000 claims description 4
• 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
• ZRSVIQCPYIYIKX-UHFFFAOYSA-N methyl 4-[[4-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxopyrrolidin-1-yl]methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CN1C(=O)CC(C=2C=C(OC3CCCC3)C(OC)=CC=2)C1 ZRSVIQCPYIYIKX-UHFFFAOYSA-N 0.000 claims description 4
• 125000004193 piperazinyl group Chemical group 0.000 claims description 4
• 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
• 125000000335 thiazolyl group Chemical group 0.000 claims description 4
• 125000001425 triazolyl group Chemical group 0.000 claims description 4
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
• AFFCCLBPSQWROV-UHFFFAOYSA-N 4-(3-cyclopentyloxy-4-methoxyphenyl)-1-[(2,4-diaminophenyl)methyl]pyrrolidin-2-one Chemical compound COC1=CC=C(C2CC(=O)N(CC=3C(=CC(N)=CC=3)N)C2)C=C1OC1CCCC1 AFFCCLBPSQWROV-UHFFFAOYSA-N 0.000 claims description 3
• 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 claims description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
• 125000005842 heteroatom Chemical group 0.000 claims description 3
• 125000000842 isoxazolyl group Chemical group 0.000 claims description 3
• 125000002757 morpholinyl group Chemical group 0.000 claims description 3
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
• 125000001715 oxadiazolyl group Chemical group 0.000 claims description 3
• 125000000160 oxazolidinyl group Chemical group 0.000 claims description 3
• 239000001301 oxygen Substances 0.000 claims description 3
• 125000003386 piperidinyl group Chemical group 0.000 claims description 3
• 125000005592 polycycloalkyl group Polymers 0.000 claims description 3
• 125000001113 thiadiazolyl group Chemical group 0.000 claims description 3
• 125000001984 thiazolidinyl group Chemical group 0.000 claims description 3
• 229930192474 thiophene Natural products 0.000 claims description 3
• DBRURKICGBSTER-GOSISDBHSA-N (4s)-1-[(4-aminophenyl)methyl]-4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-one Chemical compound COC1=CC=C([C@@H]2CC(=O)N(CC=3C=CC(N)=CC=3)C2)C=C1OC1CCCC1 DBRURKICGBSTER-GOSISDBHSA-N 0.000 claims description 2
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims description 2
• MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims description 2
• KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical compound [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 claims description 2
• CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 claims description 2
• 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 2
• 230000018044 dehydration Effects 0.000 claims description 2
• 238000006297 dehydration reaction Methods 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• 125000002632 imidazolidinyl group Chemical group 0.000 claims description 2
• 150000002466 imines Chemical class 0.000 claims description 2
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
• 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims description 2
• GMTVBECLHDYSRJ-UHFFFAOYSA-N n-[3-acetamido-4-[[4-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxopyrrolidin-1-yl]methyl]phenyl]acetamide Chemical compound COC1=CC=C(C2CC(=O)N(CC=3C(=CC(NC(C)=O)=CC=3)NC(C)=O)C2)C=C1OC1CCCC1 GMTVBECLHDYSRJ-UHFFFAOYSA-N 0.000 claims description 2
• SUXHVTWOXBFQIA-FQEVSTJZSA-N n-[4-[[(4r)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxopyrrolidin-1-yl]methyl]phenyl]acetamide Chemical compound COC1=CC=C([C@H]2CC(=O)N(CC=3C=CC(NC(C)=O)=CC=3)C2)C=C1OC1CCCC1 SUXHVTWOXBFQIA-FQEVSTJZSA-N 0.000 claims description 2
• SUXHVTWOXBFQIA-HXUWFJFHSA-N n-[4-[[(4s)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxopyrrolidin-1-yl]methyl]phenyl]acetamide Chemical compound COC1=CC=C([C@@H]2CC(=O)N(CC=3C=CC(NC(C)=O)=CC=3)C2)C=C1OC1CCCC1 SUXHVTWOXBFQIA-HXUWFJFHSA-N 0.000 claims description 2
• 230000009466 transformation Effects 0.000 claims description 2
• 101000585507 Solanum tuberosum Cytochrome b-c1 complex subunit 7 Proteins 0.000 claims 4
• 125000004104 aryloxy group Chemical group 0.000 claims 1
• 125000001188 haloalkyl group Chemical group 0.000 claims 1
• TYSMZMFTQVFYKG-UHFFFAOYSA-N n-[4-[[4-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxopyrrolidin-1-yl]methyl]phenyl]-2-oxopropanamide Chemical compound COC1=CC=C(C2CC(=O)N(CC=3C=CC(NC(=O)C(C)=O)=CC=3)C2)C=C1OC1CCCC1 TYSMZMFTQVFYKG-UHFFFAOYSA-N 0.000 claims 1
• IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 claims 1
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 231
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 228
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 201
• 239000000243 solution Substances 0.000 description 150
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 100
• 239000002904 solvent Substances 0.000 description 89
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 86
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 73
• 239000000203 mixture Substances 0.000 description 67
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 58
• 238000003818 flash chromatography Methods 0.000 description 54
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 52
• 239000012074 organic phase Substances 0.000 description 51
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 48
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 48
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 46
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 45
• 229910052938 sodium sulfate Inorganic materials 0.000 description 45
• 235000011152 sodium sulphate Nutrition 0.000 description 45
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 42
• 239000012300 argon atmosphere Substances 0.000 description 37
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 32
• 239000007787 solid Substances 0.000 description 31
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 30
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
• 229910000027 potassium carbonate Inorganic materials 0.000 description 29
• 239000011541 reaction mixture Substances 0.000 description 29
• 239000000284 extract Substances 0.000 description 27
• 238000010992 reflux Methods 0.000 description 27
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 25
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 23
• 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 23
• 239000003921 oil Substances 0.000 description 23
• 235000019198 oils Nutrition 0.000 description 23
• 239000011347 resin Substances 0.000 description 23
• 229920005989 resin Polymers 0.000 description 23
• 239000000725 suspension Substances 0.000 description 23
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 22
• 238000003756 stirring Methods 0.000 description 22
• 229910052786 argon Inorganic materials 0.000 description 21
• 210000004027 cell Anatomy 0.000 description 21
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 20
• 238000000746 purification Methods 0.000 description 20
• 239000007864 aqueous solution Substances 0.000 description 17
• 235000017557 sodium bicarbonate Nutrition 0.000 description 16
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 16
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
• 230000000694 effects Effects 0.000 description 14
• 239000008346 aqueous phase Substances 0.000 description 13
• 230000003197 catalytic effect Effects 0.000 description 13
• KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 13
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 13
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
• 241000725303 Human immunodeficiency virus Species 0.000 description 12
• SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 12
• 230000005764 inhibitory process Effects 0.000 description 12
• 229910000029 sodium carbonate Inorganic materials 0.000 description 12
• 102000013967 Monokines Human genes 0.000 description 11
• 108010050619 Monokines Proteins 0.000 description 11
• 239000002585 base Substances 0.000 description 11
• 239000000460 chlorine Substances 0.000 description 11
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 11
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
• 238000007792 addition Methods 0.000 description 10
• 210000001616 monocyte Anatomy 0.000 description 10
• HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 9
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
• 208000006673 asthma Diseases 0.000 description 9
• 239000000047 product Substances 0.000 description 9
• 239000011734 sodium Substances 0.000 description 9
• DBRURKICGBSTER-UHFFFAOYSA-N 1-[(4-aminophenyl)methyl]-4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-one Chemical compound COC1=CC=C(C2CC(=O)N(CC=3C=CC(N)=CC=3)C2)C=C1OC1CCCC1 DBRURKICGBSTER-UHFFFAOYSA-N 0.000 description 8
• 108010044467 Isoenzymes Proteins 0.000 description 8
• 210000001744 T-lymphocyte Anatomy 0.000 description 8
• 239000002253 acid Substances 0.000 description 8
• VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 8
• 238000009472 formulation Methods 0.000 description 8
• 238000001727 in vivo Methods 0.000 description 8
• 208000015181 infectious disease Diseases 0.000 description 8
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
• 150000001412 amines Chemical class 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 239000005457 ice water Substances 0.000 description 7
• 230000006433 tumor necrosis factor production Effects 0.000 description 7
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
• 241001465754 Metazoa Species 0.000 description 6
• 206010040070 Septic Shock Diseases 0.000 description 6
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
• 230000004913 activation Effects 0.000 description 6
• 239000012298 atmosphere Substances 0.000 description 6
• 239000006260 foam Substances 0.000 description 6
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 6
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 6
• 239000012312 sodium hydride Substances 0.000 description 6
• 229910000104 sodium hydride Inorganic materials 0.000 description 6
• 159000000000 sodium salts Chemical class 0.000 description 6
• 238000003786 synthesis reaction Methods 0.000 description 6
• 239000003826 tablet Substances 0.000 description 6
• XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 5
• 206010017533 Fungal infection Diseases 0.000 description 5
• 208000031886 HIV Infections Diseases 0.000 description 5
• IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 5
• 229960000583 acetic acid Drugs 0.000 description 5
• 238000004458 analytical method Methods 0.000 description 5
• 229940095074 cyclic amp Drugs 0.000 description 5
• 239000006185 dispersion Substances 0.000 description 5
• 238000000605 extraction Methods 0.000 description 5
• 239000008187 granular material Substances 0.000 description 5
• 210000002540 macrophage Anatomy 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 4
• 102000004127 Cytokines Human genes 0.000 description 4
• 108090000695 Cytokines Proteins 0.000 description 4
• 208000037357 HIV infectious disease Diseases 0.000 description 4
• 102000000589 Interleukin-1 Human genes 0.000 description 4
• 108010002352 Interleukin-1 Proteins 0.000 description 4
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
• 102000030621 adenylate cyclase Human genes 0.000 description 4
• 108060000200 adenylate cyclase Proteins 0.000 description 4
• APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 4
• ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 4
• 229940079593 drug Drugs 0.000 description 4
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 4
• 230000000670 limiting effect Effects 0.000 description 4
• ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 210000000440 neutrophil Anatomy 0.000 description 4
• 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 4
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 4
• WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
• WJUFSDZVCOTFON-UHFFFAOYSA-N veratraldehyde Chemical compound COC1=CC=C(C=O)C=C1OC WJUFSDZVCOTFON-UHFFFAOYSA-N 0.000 description 4
• VFTFKUDGYRBSAL-UHFFFAOYSA-N 15-crown-5 Chemical compound C1COCCOCCOCCOCCO1 VFTFKUDGYRBSAL-UHFFFAOYSA-N 0.000 description 3
• YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 3
• FZFWPURYSWKIRT-UHFFFAOYSA-N 3-cyclopentyloxy-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1OC1CCCC1 FZFWPURYSWKIRT-UHFFFAOYSA-N 0.000 description 3
• LDFBRTSYSGIEOK-UHFFFAOYSA-N 4-(3-cyclopentyloxy-4-methoxyphenyl)-1-[(4-methylsulfanylphenyl)methyl]pyrrolidin-2-one Chemical compound COC1=CC=C(C2CC(=O)N(CC=3C=CC(SC)=CC=3)C2)C=C1OC1CCCC1 LDFBRTSYSGIEOK-UHFFFAOYSA-N 0.000 description 3
• BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 3
• 208000030507 AIDS Diseases 0.000 description 3
• 206010001513 AIDS related complex Diseases 0.000 description 3
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
• 102000004889 Interleukin-6 Human genes 0.000 description 3
• 108090001005 Interleukin-6 Proteins 0.000 description 3
• 101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 description 3
• 208000031888 Mycoses Diseases 0.000 description 3
• 229910004298 SiO 2 Inorganic materials 0.000 description 3
• 241000700605 Viruses Species 0.000 description 3
• 239000004480 active ingredient Substances 0.000 description 3
• 210000005091 airway smooth muscle Anatomy 0.000 description 3
• 229910021529 ammonia Inorganic materials 0.000 description 3
• 150000001450 anions Chemical class 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 238000010533 azeotropic distillation Methods 0.000 description 3
• 210000003651 basophil Anatomy 0.000 description 3
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 125000004432 carbon atom Chemical group C* 0.000 description 3
• 208000023819 chronic asthma Diseases 0.000 description 3
• 239000012230 colorless oil Substances 0.000 description 3
• 238000002425 crystallisation Methods 0.000 description 3
• 230000008025 crystallization Effects 0.000 description 3
• BEPAFCGSDWSTEL-UHFFFAOYSA-N dimethyl malonate Chemical compound COC(=O)CC(=O)OC BEPAFCGSDWSTEL-UHFFFAOYSA-N 0.000 description 3
• 238000010828 elution Methods 0.000 description 3
• 239000011737 fluorine Substances 0.000 description 3
• 239000012458 free base Substances 0.000 description 3
• 230000002538 fungal effect Effects 0.000 description 3
• 239000007903 gelatin capsule Substances 0.000 description 3
• 238000000338 in vitro Methods 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 229940100601 interleukin-6 Drugs 0.000 description 3
• 210000004072 lung Anatomy 0.000 description 3
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
• 235000019341 magnesium sulphate Nutrition 0.000 description 3
• LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 3
• 238000007911 parenteral administration Methods 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• 230000010076 replication Effects 0.000 description 3
• 239000012266 salt solution Substances 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
• 210000001519 tissue Anatomy 0.000 description 3
• 230000029812 viral genome replication Effects 0.000 description 3
• DBRURKICGBSTER-SFHVURJKSA-N (4r)-1-[(4-aminophenyl)methyl]-4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-one Chemical compound COC1=CC=C([C@H]2CC(=O)N(CC=3C=CC(N)=CC=3)C2)C=C1OC1CCCC1 DBRURKICGBSTER-SFHVURJKSA-N 0.000 description 2
• FLZPTLSRDKJVLE-UHFFFAOYSA-N 1,2-dimethoxyethane-1,2-diol Chemical compound COC(O)C(O)OC FLZPTLSRDKJVLE-UHFFFAOYSA-N 0.000 description 2
• ULYWGRWLVFQXTR-UHFFFAOYSA-N 1-[(2-aminophenyl)methyl]-4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-one Chemical compound COC1=CC=C(C2CC(=O)N(CC=3C(=CC=CC=3)N)C2)C=C1OC1CCCC1 ULYWGRWLVFQXTR-UHFFFAOYSA-N 0.000 description 2
• AJEUPSQDAZSQNO-UHFFFAOYSA-N 1-[(3-aminophenyl)methyl]-4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-one Chemical compound COC1=CC=C(C2CC(=O)N(CC=3C=C(N)C=CC=3)C2)C=C1OC1CCCC1 AJEUPSQDAZSQNO-UHFFFAOYSA-N 0.000 description 2
• LVUQCTGSDJLWCE-UHFFFAOYSA-N 1-benzylpyrrolidin-2-one Chemical class O=C1CCCN1CC1=CC=CC=C1 LVUQCTGSDJLWCE-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• UVCNGQUSRPSGBT-UHFFFAOYSA-N 4-(3-cyclopentyloxy-4-methoxyphenyl)-1-[(2-nitrophenyl)methyl]pyrrolidin-2-one Chemical compound COC1=CC=C(C2CC(=O)N(CC=3C(=CC=CC=3)[N+]([O-])=O)C2)C=C1OC1CCCC1 UVCNGQUSRPSGBT-UHFFFAOYSA-N 0.000 description 2
• CTAUPQKPOXFJBA-UHFFFAOYSA-N 4-(3-cyclopentyloxy-4-methoxyphenyl)-1-[(4-hydroxyphenyl)methyl]pyrrolidin-2-one Chemical compound COC1=CC=C(C2CC(=O)N(CC=3C=CC(O)=CC=3)C2)C=C1OC1CCCC1 CTAUPQKPOXFJBA-UHFFFAOYSA-N 0.000 description 2
• SKLUWKYNZNXSLX-UHFFFAOYSA-N 4-Acetamidobenzaldehyde Chemical compound CC(=O)NC1=CC=C(C=O)C=C1 SKLUWKYNZNXSLX-UHFFFAOYSA-N 0.000 description 2
• NTBCDCWFJPRBDR-UHFFFAOYSA-N 4-[[4-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxopyrrolidin-1-yl]methyl]benzenecarbothioamide Chemical compound COC1=CC=C(C2CC(=O)N(CC=3C=CC(=CC=3)C(N)=S)C2)C=C1OC1CCCC1 NTBCDCWFJPRBDR-UHFFFAOYSA-N 0.000 description 2
• CDSIJNROOUXOCN-UHFFFAOYSA-N 4-[[4-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxopyrrolidin-1-yl]methyl]benzoic acid Chemical compound COC1=CC=C(C2CC(=O)N(CC=3C=CC(=CC=3)C(O)=O)C2)C=C1OC1CCCC1 CDSIJNROOUXOCN-UHFFFAOYSA-N 0.000 description 2
• SFEWUTRJXBPJRQ-UHFFFAOYSA-N 4-[[4-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxopyrrolidin-1-yl]methyl]benzonitrile Chemical compound COC1=CC=C(C2CC(=O)N(CC=3C=CC(=CC=3)C#N)C2)C=C1OC1CCCC1 SFEWUTRJXBPJRQ-UHFFFAOYSA-N 0.000 description 2
• RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
• VOLRSQPSJGXRNJ-UHFFFAOYSA-N 4-nitrobenzyl bromide Chemical compound [O-][N+](=O)C1=CC=C(CBr)C=C1 VOLRSQPSJGXRNJ-UHFFFAOYSA-N 0.000 description 2
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
• APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
• 206010006895 Cachexia Diseases 0.000 description 2
• 241000700199 Cavia porcellus Species 0.000 description 2
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
• VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
• 208000011231 Crohn disease Diseases 0.000 description 2
• 241000701022 Cytomegalovirus Species 0.000 description 2
• XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
• ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
• 206010014824 Endotoxic shock Diseases 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 206010028289 Muscle atrophy Diseases 0.000 description 2
• CYYKQXKXSJWCLT-UHFFFAOYSA-N N-[4-[[4-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxopyrrolidin-1-yl]methyl]phenyl]-4,5-dihydro-1,3-oxazole-2-carboxamide Chemical compound COC1=CC=C(C2CC(=O)N(CC=3C=CC(NC(=O)C=4OCCN=4)=CC=3)C2)C=C1OC1CCCC1 CYYKQXKXSJWCLT-UHFFFAOYSA-N 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• 229910000564 Raney nickel Inorganic materials 0.000 description 2
• NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
• 206010063837 Reperfusion injury Diseases 0.000 description 2
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
• 206010040047 Sepsis Diseases 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 2
• 238000009825 accumulation Methods 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 208000002205 allergic conjunctivitis Diseases 0.000 description 2
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
• CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 2
• 229960003942 amphotericin b Drugs 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 239000000427 antigen Substances 0.000 description 2
• 102000036639 antigens Human genes 0.000 description 2
• 108091007433 antigens Proteins 0.000 description 2
• 239000003443 antiviral agent Substances 0.000 description 2
• 239000011260 aqueous acid Substances 0.000 description 2
• 125000005160 aryl oxy alkyl group Chemical group 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
• BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 239000013078 crystal Substances 0.000 description 2
• XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
• 229960002986 dinoprostone Drugs 0.000 description 2
• KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
• PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
• 239000000706 filtrate Substances 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 230000006870 function Effects 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 230000014509 gene expression Effects 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 150000004820 halides Chemical class 0.000 description 2
• 238000010438 heat treatment Methods 0.000 description 2
• 210000003630 histaminocyte Anatomy 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 238000005984 hydrogenation reaction Methods 0.000 description 2
• 230000035874 hyperreactivity Effects 0.000 description 2
• 210000004969 inflammatory cell Anatomy 0.000 description 2
• 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
• JVTZFYYHCGSXJV-UHFFFAOYSA-N isovanillin Chemical compound COC1=CC=C(C=O)C=C1O JVTZFYYHCGSXJV-UHFFFAOYSA-N 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
• 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• ZXUQEPZWVQIOJE-UHFFFAOYSA-N methyl 2-chloro-2-oxoacetate Chemical compound COC(=O)C(Cl)=O ZXUQEPZWVQIOJE-UHFFFAOYSA-N 0.000 description 2
• SADZFSMJMSLPKK-UHFFFAOYSA-N n-[2-[[4-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxopyrrolidin-1-yl]methyl]phenyl]acetamide Chemical compound COC1=CC=C(C2CC(=O)N(CC=3C(=CC=CC=3)NC(C)=O)C2)C=C1OC1CCCC1 SADZFSMJMSLPKK-UHFFFAOYSA-N 0.000 description 2
• SUXHVTWOXBFQIA-UHFFFAOYSA-N n-[4-[[4-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxopyrrolidin-1-yl]methyl]phenyl]acetamide Chemical compound COC1=CC=C(C2CC(=O)N(CC=3C=CC(NC(C)=O)=CC=3)C2)C=C1OC1CCCC1 SUXHVTWOXBFQIA-UHFFFAOYSA-N 0.000 description 2
• FSYCZWWOAHSRRD-UHFFFAOYSA-N n-[5-amino-2-[[4-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxopyrrolidin-1-yl]methyl]phenyl]acetamide Chemical compound COC1=CC=C(C2CC(=O)N(CC=3C(=CC(N)=CC=3)NC(C)=O)C2)C=C1OC1CCCC1 FSYCZWWOAHSRRD-UHFFFAOYSA-N 0.000 description 2
• 210000000822 natural killer cell Anatomy 0.000 description 2
• SFDJOSRHYKHMOK-UHFFFAOYSA-N nitramide Chemical compound N[N+]([O-])=O SFDJOSRHYKHMOK-UHFFFAOYSA-N 0.000 description 2
• 150000002825 nitriles Chemical group 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 230000007310 pathophysiology Effects 0.000 description 2
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
• XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• 238000001953 recrystallisation Methods 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 238000007363 ring formation reaction Methods 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 230000036303 septic shock Effects 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
• 150000003431 steroids Chemical class 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 238000012360 testing method Methods 0.000 description 2
• HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
• VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
• 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 2
• 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 2
• 230000003827 upregulation Effects 0.000 description 2
• HJORMJIFDVBMOB-LBPRGKRZSA-N (-)-rolipram Chemical compound COC1=CC=C([C@H]2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-LBPRGKRZSA-N 0.000 description 1
• BEQHMRYBIXNFTP-UHFFFAOYSA-N (2-chlorophenyl)methyl thiocyanate Chemical compound ClC1=CC=CC=C1CSC#N BEQHMRYBIXNFTP-UHFFFAOYSA-N 0.000 description 1
• XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
• NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
• 125000004400 (C1-C12) alkyl group Chemical class 0.000 description 1
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
• IJLSYEVUXXNWGV-UHFFFAOYSA-N 1-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-one Chemical compound COC1=CC=C(N2C(CCC2)=O)C=C1OC1CCCC1 IJLSYEVUXXNWGV-UHFFFAOYSA-N 0.000 description 1
• KXIKUOQHUFWMON-UHFFFAOYSA-N 1-[(4-aminophenyl)methyl]-4-[3,4-bis(difluoromethoxy)phenyl]pyrrolidin-2-one Chemical compound C1=CC(N)=CC=C1CN1C(=O)CC(C=2C=C(OC(F)F)C(OC(F)F)=CC=2)C1 KXIKUOQHUFWMON-UHFFFAOYSA-N 0.000 description 1
• BZWQRLFHDYOUEZ-UHFFFAOYSA-N 1-[2-(4-amino-2-nitrophenyl)-1-phenylethyl]-4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-one Chemical compound COC1=CC=C(C2CC(=O)N(C(CC=3C(=CC(N)=CC=3)[N+]([O-])=O)C=3C=CC=CC=3)C2)C=C1OC1CCCC1 BZWQRLFHDYOUEZ-UHFFFAOYSA-N 0.000 description 1
• YLRBJYMANQKEAW-UHFFFAOYSA-N 1-bromo-4-(bromomethyl)benzene Chemical compound BrCC1=CC=C(Br)C=C1 YLRBJYMANQKEAW-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• OALRKTRDVLNQAZ-UHFFFAOYSA-N 1-methylsulfinyl-1-(1-methylsulfinylethylsulfanyl)ethane Chemical compound CS(=O)C(C)SC(C)S(C)=O OALRKTRDVLNQAZ-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
• 238000005160 1H NMR spectroscopy Methods 0.000 description 1
• ZILXIZUBLXVYPI-UHFFFAOYSA-N 2,4-dinitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C([N+]([O-])=O)=C1 ZILXIZUBLXVYPI-UHFFFAOYSA-N 0.000 description 1
• YTEUDCIEJDRJTM-UHFFFAOYSA-N 2-(chloromethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCl YTEUDCIEJDRJTM-UHFFFAOYSA-N 0.000 description 1
• QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 1
• CMWKITSNTDAEDT-UHFFFAOYSA-N 2-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC=C1C=O CMWKITSNTDAEDT-UHFFFAOYSA-N 0.000 description 1
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
• ZETIVVHRRQLWFW-UHFFFAOYSA-N 3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC(C=O)=C1 ZETIVVHRRQLWFW-UHFFFAOYSA-N 0.000 description 1
• SAUGHJYUGSRJQP-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)-1-[(4-nitrophenyl)methyl]pyrrolidin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1CC(=O)N(CC=2C=CC(=CC=2)[N+]([O-])=O)C1 SAUGHJYUGSRJQP-UHFFFAOYSA-N 0.000 description 1
• XZXKCFZQFFDFEE-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)-1-[[4-(dimethylamino)phenyl]methyl]pyrrolidin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1CC(=O)N(CC=2C=CC(=CC=2)N(C)C)C1 XZXKCFZQFFDFEE-UHFFFAOYSA-N 0.000 description 1
• BJLCESHFVTWEPQ-UHFFFAOYSA-N 4-(3-cyclopentyloxy-4-methoxyphenyl)-1-(methoxymethyl)pyrrolidin-2-one Chemical compound C1C(=O)N(COC)CC1C1=CC=C(OC)C(OC2CCCC2)=C1 BJLCESHFVTWEPQ-UHFFFAOYSA-N 0.000 description 1
• TUXLLOJDJYZVCI-UHFFFAOYSA-N 4-(3-cyclopentyloxy-4-methoxyphenyl)-1-(phenylmethoxymethyl)pyrrolidin-2-one Chemical compound COC1=CC=C(C2CC(=O)N(COCC=3C=CC=CC=3)C2)C=C1OC1CCCC1 TUXLLOJDJYZVCI-UHFFFAOYSA-N 0.000 description 1
• PSFSLLHBDOTTFD-UHFFFAOYSA-N 4-(3-cyclopentyloxy-4-methoxyphenyl)-1-[(2,4-dinitrophenyl)methyl]pyrrolidin-2-one Chemical compound COC1=CC=C(C2CC(=O)N(CC=3C(=CC(=CC=3)[N+]([O-])=O)[N+]([O-])=O)C2)C=C1OC1CCCC1 PSFSLLHBDOTTFD-UHFFFAOYSA-N 0.000 description 1
• PCNSLPRGHDFEDZ-UHFFFAOYSA-N 4-(3-cyclopentyloxy-4-methoxyphenyl)-1-[(3-nitrophenyl)methyl]pyrrolidin-2-one Chemical compound COC1=CC=C(C2CC(=O)N(CC=3C=C(C=CC=3)[N+]([O-])=O)C2)C=C1OC1CCCC1 PCNSLPRGHDFEDZ-UHFFFAOYSA-N 0.000 description 1
• XGFAUASWPFRANU-UHFFFAOYSA-N 4-(3-cyclopentyloxy-4-methoxyphenyl)-1-[(4-methylsulfonylphenyl)methyl]pyrrolidin-2-one Chemical compound COC1=CC=C(C2CC(=O)N(CC=3C=CC(=CC=3)S(C)(=O)=O)C2)C=C1OC1CCCC1 XGFAUASWPFRANU-UHFFFAOYSA-N 0.000 description 1
• XPHLJKJVGBOLLF-UHFFFAOYSA-N 4-(3-cyclopentyloxy-4-methoxyphenyl)-1-[[4-(dimethylamino)phenyl]methyl]pyrrolidin-2-one Chemical compound COC1=CC=C(C2CC(=O)N(CC=3C=CC(=CC=3)N(C)C)C2)C=C1OC1CCCC1 XPHLJKJVGBOLLF-UHFFFAOYSA-N 0.000 description 1
• WZWIQYMTQZCSKI-UHFFFAOYSA-N 4-cyanobenzaldehyde Chemical compound O=CC1=CC=C(C#N)C=C1 WZWIQYMTQZCSKI-UHFFFAOYSA-N 0.000 description 1
• PIMQQGJMDMAZGT-UHFFFAOYSA-N 4-methylthiobenzaldehyde Chemical compound CC1=CC=C(C=S)C=C1 PIMQQGJMDMAZGT-UHFFFAOYSA-N 0.000 description 1
• BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
• AEOBEOJCBAYXBA-UHFFFAOYSA-N A2P5P Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1OP(O)(O)=O AEOBEOJCBAYXBA-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
• 229930183010 Amphotericin Natural products 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 101100439664 Arabidopsis thaliana CHR8 gene Proteins 0.000 description 1
• 235000003911 Arachis Nutrition 0.000 description 1
• 244000105624 Arachis hypogaea Species 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 206010006458 Bronchitis chronic Diseases 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• 102000000584 Calmodulin Human genes 0.000 description 1
• 108010041952 Calmodulin Proteins 0.000 description 1
• 241000222122 Candida albicans Species 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 229920002284 Cellulose triacetate Polymers 0.000 description 1
• 206010063094 Cerebral malaria Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
• 206010012438 Dermatitis atopic Diseases 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical group NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
• 201000005569 Gout Diseases 0.000 description 1
• 206010018634 Gouty Arthritis Diseases 0.000 description 1
• 206010020164 HIV infection CDC Group III Diseases 0.000 description 1
• 208000009889 Herpes Simplex Diseases 0.000 description 1
• 208000007514 Herpes zoster Diseases 0.000 description 1
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
• 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 239000002841 Lewis acid Substances 0.000 description 1
• 108010074338 Lymphokines Proteins 0.000 description 1
• 102000008072 Lymphokines Human genes 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 206010027236 Meningitis fungal Diseases 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
• LAHIIHJGNLUPCC-UHFFFAOYSA-N N-[3-amino-4-[[4-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxopyrrolidin-1-yl]methyl]phenyl]acetamide Chemical compound COC1=CC=C(C2CC(=O)N(CC=3C(=CC(NC(C)=O)=CC=3)N)C2)C=C1OC1CCCC1 LAHIIHJGNLUPCC-UHFFFAOYSA-N 0.000 description 1
• ULFPIVLMAQLOBU-UHFFFAOYSA-N N-[4-[[4-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxopyrrolidin-1-yl]methyl]phenyl]methanesulfonamide Chemical compound COC1=CC=C(C2CC(=O)N(CC=3C=CC(NS(C)(=O)=O)=CC=3)C2)C=C1OC1CCCC1 ULFPIVLMAQLOBU-UHFFFAOYSA-N 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 206010028980 Neoplasm Diseases 0.000 description 1
• 235000019502 Orange oil Nutrition 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 108010040201 Polymyxins Proteins 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 101100212791 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YBL068W-A gene Proteins 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 244000000231 Sesamum indicum Species 0.000 description 1
• 235000003434 Sesamum indicum Nutrition 0.000 description 1
• 201000010001 Silicosis Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• 230000006044 T cell activation Effects 0.000 description 1
• 206010044248 Toxic shock syndrome Diseases 0.000 description 1
• 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
• 208000024780 Urticaria Diseases 0.000 description 1
• 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
• SMPQPSXICCBYOO-UHFFFAOYSA-N [4-[[4-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxopyrrolidin-1-yl]methyl]phenyl] acetate Chemical compound COC1=CC=C(C2CC(=O)N(CC=3C=CC(OC(C)=O)=CC=3)C2)C=C1OC1CCCC1 SMPQPSXICCBYOO-UHFFFAOYSA-N 0.000 description 1
• NFGODEMQGQNUKK-UHFFFAOYSA-M [6-(diethylamino)-9-(2-octadecoxycarbonylphenyl)xanthen-3-ylidene]-diethylazanium;chloride Chemical group [Cl-].CCCCCCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1C1=C2C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C21 NFGODEMQGQNUKK-UHFFFAOYSA-M 0.000 description 1
• ZGSDJMADBJCNPN-UHFFFAOYSA-N [S-][NH3+] Chemical compound [S-][NH3+] ZGSDJMADBJCNPN-UHFFFAOYSA-N 0.000 description 1
• DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
• 150000001241 acetals Chemical class 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 210000005057 airway smooth muscle cell Anatomy 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 150000004703 alkoxides Chemical class 0.000 description 1
• 125000003282 alkyl amino group Chemical group 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 239000000908 ammonium hydroxide Substances 0.000 description 1
• UYJXRRSPUVSSMN-UHFFFAOYSA-P ammonium sulfide Chemical compound [NH4+].[NH4+].[S-2] UYJXRRSPUVSSMN-UHFFFAOYSA-P 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 238000005349 anion exchange Methods 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000000843 anti-fungal effect Effects 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 239000000924 antiasthmatic agent Substances 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 210000000709 aorta Anatomy 0.000 description 1
• 230000002917 arthritic effect Effects 0.000 description 1
• 125000003710 aryl alkyl group Chemical group 0.000 description 1
• 210000001130 astrocyte Anatomy 0.000 description 1
• 208000024998 atopic conjunctivitis Diseases 0.000 description 1
• 201000008937 atopic dermatitis Diseases 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• HYGWNUKOUCZBND-UHFFFAOYSA-N azanide Chemical compound [NH2-] HYGWNUKOUCZBND-UHFFFAOYSA-N 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• IULFXBLVJIPESI-UHFFFAOYSA-N bis(methylsulfanyl)methylidenecyanamide Chemical compound CSC(SC)=NC#N IULFXBLVJIPESI-UHFFFAOYSA-N 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 208000019664 bone resorption disease Diseases 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 239000012267 brine Substances 0.000 description 1
• ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 1
• 206010006451 bronchitis Diseases 0.000 description 1
• 230000001593 cAMP accumulation Effects 0.000 description 1
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
• 229940095731 candida albicans Drugs 0.000 description 1
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
• 230000007248 cellular mechanism Effects 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 208000015114 central nervous system disease Diseases 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 208000007451 chronic bronchitis Diseases 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 229960004022 clotrimazole Drugs 0.000 description 1
• VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 235000008504 concentrate Nutrition 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 229960000265 cromoglicic acid Drugs 0.000 description 1
• 239000012043 crude product Substances 0.000 description 1
• 235000007336 cyanidin Nutrition 0.000 description 1
• 125000004093 cyano group Chemical group *C#N 0.000 description 1
• QPJDMGCKMHUXFD-UHFFFAOYSA-N cyanogen chloride Chemical compound ClC#N QPJDMGCKMHUXFD-UHFFFAOYSA-N 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
• 238000000354 decomposition reaction Methods 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 201000010064 diabetes insipidus Diseases 0.000 description 1
• 125000005265 dialkylamine group Chemical group 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• PBWZKZYHONABLN-UHFFFAOYSA-N difluoroacetic acid Chemical compound OC(=O)C(F)F PBWZKZYHONABLN-UHFFFAOYSA-N 0.000 description 1
• IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
• VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 230000009109 downstream regulation Effects 0.000 description 1
• 229960003913 econazole Drugs 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 208000003401 eosinophilic granuloma Diseases 0.000 description 1
• 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
• KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
• 229960001123 epoprostenol Drugs 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 235000019441 ethanol Nutrition 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 230000005713 exacerbation Effects 0.000 description 1
• 239000003925 fat Substances 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 229960004884 fluconazole Drugs 0.000 description 1
• RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
• 201000010056 fungal meningitis Diseases 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 239000012362 glacial acetic acid Substances 0.000 description 1
• 230000002518 glial effect Effects 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 239000010440 gypsum Substances 0.000 description 1
• 229910052602 gypsum Inorganic materials 0.000 description 1
• 238000011905 homologation Methods 0.000 description 1
• 150000004678 hydrides Chemical class 0.000 description 1
• LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical class N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
• 150000002460 imidazoles Chemical class 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• 239000013067 intermediate product Substances 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
• NIZHERJWXFHGGU-UHFFFAOYSA-N isocyanato(trimethyl)silane Chemical compound C[Si](C)(C)N=C=O NIZHERJWXFHGGU-UHFFFAOYSA-N 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 208000011379 keloid formation Diseases 0.000 description 1
• 229960004125 ketoconazole Drugs 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 150000007517 lewis acids Chemical class 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
• 229910003002 lithium salt Inorganic materials 0.000 description 1
• 159000000002 lithium salts Chemical class 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
• 229910001623 magnesium bromide Inorganic materials 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 229910052987 metal hydride Inorganic materials 0.000 description 1
• 150000004681 metal hydrides Chemical class 0.000 description 1
• 229940071648 metered dose inhaler Drugs 0.000 description 1
• UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
• YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
• FEIOASZZURHTHB-UHFFFAOYSA-N methyl 4-formylbenzoate Chemical compound COC(=O)C1=CC=C(C=O)C=C1 FEIOASZZURHTHB-UHFFFAOYSA-N 0.000 description 1
• XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
• 229940017219 methyl propionate Drugs 0.000 description 1
• XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• 210000005087 mononuclear cell Anatomy 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
• LFSZLTUNAORFFB-UHFFFAOYSA-N n-[2-[[4-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxopyrrolidin-1-yl]methyl]-5-nitrophenyl]acetamide Chemical compound COC1=CC=C(C2CC(=O)N(CC=3C(=CC(=CC=3)[N+]([O-])=O)NC(C)=O)C2)C=C1OC1CCCC1 LFSZLTUNAORFFB-UHFFFAOYSA-N 0.000 description 1
• SYTHZEZMUMAGHJ-UHFFFAOYSA-N n-[4-[[4-(3,4-dimethoxyphenyl)-2-oxopyrrolidin-1-yl]methyl]phenyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1C1CC(=O)N(CC=2C=CC(NC(C)=O)=CC=2)C1 SYTHZEZMUMAGHJ-UHFFFAOYSA-N 0.000 description 1
• XPOHHUOICIXCRE-UHFFFAOYSA-N n-[4-[[4-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxopyrrolidin-1-yl]methyl]-3-nitrophenyl]acetamide Chemical compound COC1=CC=C(C2CC(=O)N(CC=3C(=CC(NC(C)=O)=CC=3)[N+]([O-])=O)C2)C=C1OC1CCCC1 XPOHHUOICIXCRE-UHFFFAOYSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 125000002560 nitrile group Chemical group 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 229910000510 noble metal Inorganic materials 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 239000010502 orange oil Substances 0.000 description 1
• 239000012044 organic layer Substances 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
• 238000005192 partition Methods 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 238000001050 pharmacotherapy Methods 0.000 description 1
• FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
• 239000011505 plaster Substances 0.000 description 1
• 229940041153 polymyxins Drugs 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• 238000002953 preparative HPLC Methods 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 239000003223 protective agent Substances 0.000 description 1
• 108090000623 proteins and genes Proteins 0.000 description 1
• 102000004169 proteins and genes Human genes 0.000 description 1
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
• 150000004040 pyrrolidinones Chemical class 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 229950005741 rolipram Drugs 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 229910000077 silane Inorganic materials 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• ZVCDLGYNFYZZOK-UHFFFAOYSA-M sodium cyanate Chemical compound [Na]OC#N ZVCDLGYNFYZZOK-UHFFFAOYSA-M 0.000 description 1
• 235000009518 sodium iodide Nutrition 0.000 description 1
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• 125000000547 substituted alkyl group Chemical group 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 150000003512 tertiary amines Chemical class 0.000 description 1
• 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 150000003852 triazoles Chemical class 0.000 description 1
• 229940029284 trichlorofluoromethane Drugs 0.000 description 1
• LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1
• 238000000825 ultraviolet detection Methods 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 239000012178 vegetable wax Substances 0.000 description 1
• 238000009423 ventilation Methods 0.000 description 1
• 201000005539 vernal conjunctivitis Diseases 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 238000005406 washing Methods 0.000 description 1